Latest 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
Alset Inc. filed its Q3 2026 10-Q, revealing a net loss for the nine-month period, a decrease in cash, and ongoing operational challenges, though it also reported gains from deconsolidation and increased investment securities.
NASDAQ
Perpetua Resources Corp. reported a substantial increase in net loss for the nine months ended September 30, 2026, driven by higher exploration and pre-development expenses, while advancing its Stibnite Gold Project and awaiting crucial financing.
NASDAQ
Dragonfly Energy Holdings Corp. reported a net loss of $5.5 million for Q3 2026, with net sales down 23.8% year-over-year, while facing ongoing going concern uncertainties.
NASDAQ
Syntec Optics Holdings, Inc. announced a substantial increase in net sales and a significant improvement in profitability for the third quarter ended September 30, 2026, driven by strong performance in Defense Tech and Space Tech segments.
NASDAQ
Eightco Holdings Inc. reported a dramatic 98.3% revenue drop in Q3 2026 compared to the prior year, primarily due to issues with its largest customer, while digital asset gains offset operating losses.
NASDAQ
Fifth Era Acquisition Corp I reports Q3 2026 financials, highlighting progress on its Miotal business combination while facing Nasdaq listing compliance issues.
OID
Awaysis Capital, Inc. reported increased revenues but highlighted substantial going concern risks, operating losses, and significant debt maturities in its Q1 2027 Form 10-Q filing.
Forum Markets, Inc. (formerly ETHZilla Corporation) filed its Q3 2026 Form 10-Q, detailing a strategic shift towards AI infrastructure and aircraft engine rentals, while reporting a net loss and a material weakness in internal controls.
NASDAQ
Tempest Therapeutics' Q3 2026 report highlights substantial going concern doubts and Nasdaq listing non-compliance risks, alongside ongoing clinical development and capital-raising efforts.
NASDAQ
CISO Global, Inc. filed its Q3 2026 Form 10-Q, revealing continued operating losses, a significant working capital deficit, and substantial doubt about its ability to continue as a going concern, though it has implemented cost reductions.
NASDAQ
RTB Digital, Inc. announced its third-quarter 2026 financial results, showcasing a substantial increase in revenue driven by its Fintech Operations segment, but also reporting a significant rise in net losses and operating expenses.
NASDAQ
GBank Financial Holdings Inc. reported a decrease in net income for the third quarter of 2026 compared to the prior year, driven by increased provisions for credit losses and a rise in non-performing assets, despite overall loan portfolio growth.
NASDAQ
Talon Capital Corp. announced its quarterly report for the period ending September 30, 2026, detailing net income and significant trust account balances.
NASDAQ
Silvia, Inc. (SVIA) filed its Q3 2026 10-Q, revealing substantial unrealized gains on its Bitcoin holdings, offset by significant operating expenses and a notable working capital deficit.
NASDAQ
Canary Staked SUI ETF's Q3 2026 report shows significant net asset value growth, primarily due to a substantial appreciation in SUI value and successful staking rewards.
NASDAQ
Thayer Ventures Acquisition Corporation II filed its Q3 2026 10-Q, reporting net income driven by investment earnings and a California franchise tax benefit, while continuing its search for a business combination.
NASDAQ
Canary Marinade Solana ETF's Q3 2026 report shows a substantial increase in net assets driven by Solana's price appreciation and increased share creation.
NASDAQ
Cingulate Inc. reported its Q3 2026 results, highlighting a net loss of $7.7 million and a significant increase in SG&A expenses, alongside a Complete Response Letter from the FDA for its lead drug candidate, CTx-1301.
NASDAQ
The 21Shares Hyperliquid Staking ETF (THYP) reported a significant increase in Net Asset Value (NAV) for the quarter ended September 30, 2026, driven by substantial appreciation in its HYPE holdings and successful staking rewards.
NASDAQ
K2 Capital Acquisition Corp. reports on its financial condition and operational status for the quarter ended September 30, 2026, highlighting its ongoing search for a business combination and its financial position.
NASDAQ
Gesher Acquisition Corp. II files its Q3 2026 Form 10-Q, reporting on its financial status and ongoing search for a business combination target, with a focus on Israeli companies.
OTC.Pink
CoJax Oil and Gas Corporation's Q3 2026 Form 10-Q reveals a significant revenue increase driven by higher oil prices and production, yet the company continues to face substantial doubt regarding its ability to continue as a going concern.
NASDAQ
Apogee Acquisition Corp's Q3 2026 10-Q filing reveals continued focus on identifying a business combination, with significant investment income offset by operational expenses and substantial doubts about its ability to continue as a going concern.
NASDAQ
Inflection Point Acquisition Corp. VII reports on its progress towards a business combination with Elroy Air, detailing financial status and strategic agreements as of September 30, 2026.
NASDAQ
Enhanced Group Inc. filed its Q3 2026 Form 10-Q, detailing a net loss of $13.5 million and highlighting substantial doubt about its ability to continue as a going concern, while also announcing strategic developments including a proposed acquisition and the launch of Enhanced OS.
Amaze Holdings, Inc. reported a significant 63% year-over-year revenue decline for the third quarter of 2026, alongside a substantial net loss and delisting from the NYSE American.
NASDAQ
Health In Tech, Inc. reported a net loss of $7.1 million for Q3 2026, driven by increased credit loss provisions and a decline in revenues, while also securing new financing and announcing leadership transitions.
OQB
Nuo Therapeutics, Inc. reported increased revenues for Q3 2026, but continues to face substantial doubt regarding its ability to continue as a going concern.
NASDAQ
Pasithea Therapeutics reported a net loss of $6.58 million for Q3 2026, with research and development expenses surging by 228.3% year-over-year, while cash reserves decreased significantly.
NYSE
Metals Acquisition Corp. II reports on its third quarter ending September 30, 2026, detailing its financial position post-IPO and ongoing efforts to identify a suitable business combination.